Wedbush Cuts Earnings Estimates for BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at Wedbush lowered their FY2026 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Wednesday, October 15th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $0.47 for the year, down from their prior forecast of $0.80. Wedbush currently has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q4 2026 earnings at $0.13 EPS, FY2027 earnings at $0.56 EPS and FY2029 earnings at $1.85 EPS.

Several other analysts also recently commented on BCRX. Evercore ISI restated an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Zacks Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Royal Bank Of Canada restated an “outperform” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.18.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $6.63 on Friday. The company has a market capitalization of $1.39 billion, a P/E ratio of -36.83, a price-to-earnings-growth ratio of 0.78 and a beta of 1.05. The company’s 50 day moving average price is $7.84 and its two-hundred day moving average price is $8.64. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. The business’s quarterly revenue was up 49.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) earnings per share.

Insider Activity

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director directly owned 65,352 shares in the company, valued at $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. State Street Corp increased its holdings in BioCryst Pharmaceuticals by 8.9% during the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock worth $76,208,000 after buying an additional 691,988 shares during the last quarter. Alkeon Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 1.7% during the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock worth $54,105,000 after buying an additional 120,199 shares during the last quarter. Geode Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock worth $45,296,000 after buying an additional 93,973 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock worth $38,336,000 after buying an additional 4,084,403 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after buying an additional 3,022,769 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.